Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems?

AIMS This study used spontaneous reports of adverse events to estimate the risk for developing cardiac arrhythmias due to the systemic use of non-sedating antihistamine drugs and compared the risk estimate before and after the regulatory action to recall the over-the-counter status of some of these drugs. METHODS All suspected adverse drug reactions (ADRs) reported until July 1999 to the Netherlands Pharmacovigilance Foundation Lareb were used to calculate the ADR reporting odds ratio, defined as the ratio of exposure odds among reported arrhythmia cases, to the exposure odds of other ADRs (non-cases), adjusted for gender, age, reporter, year of reporting and comedication, stratified for the periods before and after the governmental decision in the Netherlands. RESULTS Seven-hundred and thirty-seven cases of arrhythmia were reported, out of which there were 43 instances where the patients were using non-sedating antihistamines. In general non-sedating antihistamines are associated with cardiac arrhythmia to a higher extent in comparison with other drugs (ADR reporting odds ratio 2.05 [95% CI: 1.45, 2.89]). The association between arrhythmias and non-sedating antihistamine drugs calculated before 1998 was not significantly higher than 1 (OR 1.37 [95% CI: 0.85, 2.23]), whereas the risk estimate calculated after the governmental decision did significantly differ from 1 (OR 4.19 [95% CI: 2.49, 7.05]). CONCLUSIONS Our data suggest that non-sedating antihistamines might have an increased risk for inducing arrhythmias. Our findings, however, strongly suggest that the increased risk identified can at least partly be explained by reporting bias as a result of publications about and mass media attention for antihistamine induced arrhythmias.

[1]  D. J. Finney,et al.  stematic Signalling of Adverse Reactions to Drugs , 1974, Methods of Information in Medicine.

[2]  Gerald A. Faich,et al.  Factors Affecting Physician Reporting of Adverse Drug Reactions , 1986 .

[3]  C. E. Lumley,et al.  The under-reporting of adverse drug reactions seen in general practice , 1986 .

[4]  A. Pelech,et al.  ASTEMIZOLE-INDUCED TORSADE DE POINTES , 1988, The Lancet.

[5]  J. Vandenbroucke,et al.  QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population , 1991, Circulation.

[6]  B McNutt,et al.  Torsades de pointes occurring in association with terfenadine use. , 1991, JAMA.

[7]  B. Stricker,et al.  Serum sickness-like reactions to cefaclor. , 1992, Journal of clinical epidemiology.

[8]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[9]  P. Schad,et al.  Loratadine and ventricular tachycardia. , 1994, The American journal of cardiology.

[10]  R. Meyboom,et al.  Non-puerperal lactation associated with antidepressant drug use. , 2003, British journal of clinical pharmacology.

[11]  L. Wilton,et al.  Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study , 1998, BMJ.

[12]  B. Knollmann,et al.  Cardiac actions of erythromycin: influence of female sex. , 1998, JAMA.

[13]  J A Kors,et al.  Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. , 1999, European heart journal.

[14]  Arthur J. Moss,et al.  The QT Interval and Torsade de Pointes , 1999, Drug safety.

[15]  F. D. de Abajo,et al.  Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. , 1999, British journal of clinical pharmacology.

[16]  R. Meyboom,et al.  Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. , 1999, British journal of clinical pharmacology.

[17]  G. Pearce,et al.  QT lengthening and life-threatening arrhythmias associated with fexofenadine. , 2000, The British journal of general practice : the journal of the Royal College of General Practitioners.

[18]  A. Hoes,et al.  Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. , 2000, Archives of internal medicine.